Search results
Results from the WOW.Com Content Network
Amgen (NASDAQ: AMGN) stock is up 13% this year but has struggled to break out above a tight trading range in recent months. Despite a string of solid earnings reports from the biotechnology giant ...
Shares of Amgen (NASDAQ: AMGN) are down by 6% in the last 30 days as I write this -- a larger-than-normal amount for a large pharma company's stock to fall, especially considering that the market ...
While Amgen's (NASDAQ: AMGN) shares have underperformed the market over the past 12 months, climbing 19.7% compared to the market's unusually large gain of 35.6%, there's no shortage of reasons to ...
The biotech industry can be volatile even for relatively large companies. Amgen (NASDAQ: AMGN), one of the more prominent names in the game, just reminded us all of that fact. Let's find out what ...
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Amgen wasn’t one of them. The 10 stocks that made the cut ...
Amgen's market-beating ways are unlikely to evaporate any time soon.
Amgen shares trade at just 13.4 times forward earnings, a remarkable discount to the S&P 500's multiple of nearly 24. This valuation gap seems overdone, given Amgen's cash-generating power.
Given the S&P 500's inflated levels right now and the potential for a correction in the future, I don't think it's a big leap to predict that Amgen will be a market-beating stock over the next ...